XML 225 R14.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Segment Information | 12 Months Ended
--- | ---
Dec. 31, 2023
Segment Reporting, Measurement Disclosures [Abstract] |
Segment Information | SEGMENT INFORMATION In the fourth quarter of 2022, the Company realigned its reportable segments to reflect changes in the Company’s internal organization resulting from the rate of growth within certain of the Company’s businesses in the former Life Sciences segment. There was no change to the Company’s Diagnostics segment. Prior period segment amounts have been restated to conform to the revised segment presentation. The Company operates and reports its results in three separate business segments consisting of the Biotechnology, Life Sciences and Diagnostics segments. Operating profit represents total revenues less operating expenses, excluding nonoperating income and expense, loss on early extinguishment of borrowings, interest and income taxes. Operating profit amounts in the Other segment consist of unallocated corporate costs and other costs not considered part of management’s evaluation of reportable segment operating performance. The identifiable assets by segment are those used in each segment’s operations. Intersegment amounts are not significant and are eliminated to arrive at consolidated totals. Detailed segment data for the years ended December 31 is as follows ($ in millions):
| 2023 |  | 2022 |  | 2021
Sales: |  |  |  |  |
Biotechnology | $ | 7,172 |  |  | $ | 8,758 |  |  | $ | 8,570 |
Life Sciences | 7,141 |  |  | 7,036 |  |  | 6,388 |
Diagnostics | 9,577 |  |  | 10,849 |  |  | 9,844 |
Total | $ | 23,890 |  |  | $ | 26,643 |  |  | $ | 24,802 |
Operating profit: |  |  |  |  |
Biotechnology | $ | 1,909 |  |  | $ | 3,008 |  |  | $ | 3,074 |
Life Sciences | 1,209 |  |  | 1,414 |  |  | 1,293 |
Diagnostics | 2,406 |  |  | 3,436 |  |  | 2,313 |
Other | (322) |  |  | (322) |  |  | (303) |
Total | $ | 5,202 |  |  | $ | 7,536 |  |  | $ | 6,377 |
Depreciation and amortization of intangible assets: |  |  |  |  |
Biotechnology | $ | 1,026 |  |  | $ | 1,002 |  |  | $ | 1,059 |
Life Sciences | 558 |  |  | 531 |  |  | 382 |
Diagnostics | 577 |  |  | 590 |  |  | 614 |
Other | 5 |  |  | 9 |  |  | 7 |
Total | $ | 2,166 |  |  | $ | 2,132 |  |  | $ | 2,062 |
The following table presents additional detailed segment data for the years ended December 31 ($ in millions):
| 2023 |  | 2022 |  | 2021
Identifiable assets: |  |  |  |  |
Biotechnology | $ | 37,421 |  |  | $ | 37,536 |  |  | $ | 38,118 |
Life Sciences | 23,730 |  |  | 17,572 |  |  | 19,768 |
Diagnostics | 14,552 |  |  | 14,722 |  |  | 15,054 |
Other | 8,785 |  |  | 9,739 |  |  | 5,407 |
Discontinued operations | — |  |  | 4,781 |  |  | 4,837 |
Total | $ | 84,488 |  |  | $ | 84,350 |  |  | $ | 83,184 |
Capital expenditures, gross: |  |  |  |  |
Biotechnology | $ | 417 |  |  | $ | 405 |  |  | $ | 385 |
Life Sciences | 320 |  |  | 325 |  |  | 210 |
Diagnostics | 546 |  |  | 382 |  |  | 644 |
Other | 100 |  |  | 6 |  |  | 1 |
Total | $ | 1,383 |  |  | $ | 1,118 |  |  | $ | 1,240 |
Operations in Geographical Areas:
| Year Ended December 31
($ in millions) | 2023 |  | 2022 |  | 2021
Sales: |  |  |  |  |
United States | $ | 9,579 |  |  | $ | 11,289 |  |  | $ | 9,411 |
China | 3,143 |  |  | 3,611 |  |  | 3,565 |
All other (each country individually less than 5% of total sales) | 11,168 |  |  | 11,743 |  |  | 11,826 |
Total | $ | 23,890 |  |  | $ | 26,643 |  |  | $ | 24,802 |
Property, plant and equipment, net: |  |  |  |  |
United States | $ | 2,304 |  |  | $ | 1,839 |  |  | $ | 1,628 |
Sweden | 425 |  |  | 429 |  |  | 513 |
United Kingdom | 371 |  |  | 239 |  |  | 244 |
Germany | 238 |  |  | 204 |  |  | 200 |
All other (each country individually less than 5% of total property, plant and equipment, net) | 1,215 |  |  | 998 |  |  | 945 |
Total | $ | 4,553 |  |  | $ | 3,709 |  |  | $ | 3,530 |

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-15 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//280/tableOfContent Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-26 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-34 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingMeasurementDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration